{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:33:21Z","timestamp":1776692001105,"version":"3.51.2"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.intimp.2021.108463","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T12:05:28Z","timestamp":1640088328000},"page":"108463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2296-8675","authenticated-orcid":false,"given":"Mohamed E.","family":"Shaker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omnia M.","family":"Hendawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2649-3002","authenticated-orcid":false,"given":"Mohamed","family":"El-Mesery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara H.","family":"Hazem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2021.108463_b0005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41392-021-00679-0","article-title":"The signal pathways and treatment of cytokine storm in COVID-19","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"8","key":"10.1016\/j.intimp.2021.108463_b0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.tips.2020.06.007","article-title":"Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19","volume":"41","author":"Luo","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2021.108463_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2020.10.001","article-title":"Liver disease and outcomes among COVID-19 hospitalized patients - A systematic review and meta-analysis","volume":"21","author":"Sharma","year":"2021","journal-title":"Ann. Hepatol."},{"issue":"19","key":"10.1016\/j.intimp.2021.108463_b0020","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.3748\/wjg.v26.i19.2286","article-title":"Liver diseases in COVID-19: Etiology, treatment and prognosis","volume":"26","author":"Wu","year":"2020","journal-title":"World J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.intimp.2021.108463_b0025","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci."},{"issue":"5","key":"10.1016\/j.intimp.2021.108463_b0030","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/lt.22036","article-title":"Blockade of Janus kinase-2 signaling ameliorates mouse liver damage due to ischemia and reperfusion","volume":"16","author":"Freitas","year":"2010","journal-title":"Liver Transpl."},{"issue":"9","key":"10.1016\/j.intimp.2021.108463_b0035","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1074\/jbc.M116.752519","article-title":"Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice","volume":"292","author":"Shi","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.intimp.2021.108463_b0040","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3892\/ijmm.2016.2692","article-title":"Targeted blockade of JAK\/STAT3 signaling inhibits proliferation, migration and collagen production as well as inducing the apoptosis of hepatic stellate cells","volume":"38","author":"Gu","year":"2016","journal-title":"Int. J. Mol. Med."},{"issue":"4","key":"10.1016\/j.intimp.2021.108463_b0045","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.coph.2012.06.008","article-title":"Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease","volume":"12","author":"Kontzias","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2021.108463_b0050","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","article-title":"Janus kinases to jakinibs: from basic insights to clinical practice","volume":"58","author":"Gadina","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.intimp.2021.108463_b0055","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","article-title":"FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease","volume":"25","author":"Przepiorka","year":"2020","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.intimp.2021.108463_b0060","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2021.108463_b0065","first-page":"75","article-title":"Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera","volume":"8","author":"Raedler","year":"2015","journal-title":"Am. Health Drug Benefits"},{"issue":"7","key":"10.1016\/j.intimp.2021.108463_b0070","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41375-020-0891-0","article-title":"The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation","volume":"34","author":"La Ros\u00e9e","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.intimp.2021.108463_b0075","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/ph14080738","article-title":"Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues","volume":"14","author":"Gatti","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.intimp.2021.108463_b0080","article-title":"The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis","volume":"11","author":"Wijaya","year":"2021","journal-title":"Clin. Epidemiol. Glob Health"},{"issue":"1","key":"10.1016\/j.intimp.2021.108463_b0085","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1172\/JCI115836","article-title":"A T cell-dependent experimental liver injury in mice inducible by concanavalin A","volume":"90","author":"Tiegs","year":"1992","journal-title":"J. Clin. Invest."},{"issue":"1 Suppl","key":"10.1016\/j.intimp.2021.108463_b0090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0023677215572841","article-title":"The concanavalin A model of acute hepatitis in mice","volume":"49","author":"Heymann","year":"2015","journal-title":"Lab. Anim."},{"key":"10.1016\/j.intimp.2021.108463_b0095","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"issue":"3","key":"10.1016\/j.intimp.2021.108463_b0100","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1432-1033.1974.tb03714.x","article-title":"Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase","volume":"47","author":"Marklund","year":"1974","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.intimp.2021.108463_b0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.toxlet.2016.08.015","article-title":"The novel c-Met inhibitor capmatinib mitigates diethylnitrosamine acute liver injury in mice","volume":"261","author":"Shaker","year":"2016","journal-title":"Toxicol. Lett."},{"issue":"1","key":"10.1016\/j.intimp.2021.108463_b0110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0304-4165(79)90289-7","article-title":"Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver","volume":"582","author":"Moron","year":"1979","journal-title":"Biochim. Biophys. Acta"},{"issue":"22","key":"10.1016\/j.intimp.2021.108463_b0115","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1016\/S0021-9258(19)42083-8","article-title":"Glutathione S-transferases. The first enzymatic step in mercapturic acid formation","volume":"249","author":"Habig","year":"1974","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.intimp.2021.108463_b0120","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1021\/tx9701790","article-title":"Reactions of 1-methyl-2-phenylindole with malondialdehyde and 4-hydroxyalkenals. Analytical applications to a colorimetric assay of lipid peroxidation","volume":"11","author":"Gerard-Monnier","year":"1998","journal-title":"Chem. Res. Toxicol."},{"issue":"1","key":"10.1016\/j.intimp.2021.108463_b0125","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1006\/niox.2000.0319","article-title":"A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite","volume":"5","author":"Miranda","year":"2001","journal-title":"Nitric Oxide"},{"issue":"3","key":"10.1016\/j.intimp.2021.108463_b0130","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0160-5402(90)90061-O","article-title":"Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity","volume":"23","author":"Schierwagen","year":"1990","journal-title":"J. Pharmacol. Methods"},{"issue":"1","key":"10.1016\/j.intimp.2021.108463_b0135","first-page":"190","article-title":"Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor","volume":"21","author":"Gantner","year":"1995","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.intimp.2021.108463_b0140","first-page":"1608","article-title":"Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis","volume":"23","author":"Mizuhara","year":"1996","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.intimp.2021.108463_b0145","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.4049\/jimmunol.159.3.1418","article-title":"Suppression of concanavalin A-induced hepatitis in IFN-gamma(-\/-) mice, but not in TNF-alpha(-\/-) mice: role for IFN-gamma in activating apoptosis of hepatocytes","volume":"159","author":"Tagawa","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.108463_b0150","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3389\/fimmu.2018.00758","article-title":"NOD-Like Receptor Protein 3 Inflammasome-Dependent IL-1\u03b2 Accelerated ConA-Induced Hepatitis","volume":"9","author":"Luan","year":"2018","journal-title":"Front. Immunol."},{"issue":"4\u20135","key":"10.1016\/j.intimp.2021.108463_b0155","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.imbio.2017.11.001","article-title":"Macrophages: Their role, activation and polarization in pulmonary diseases","volume":"223","author":"Arora","year":"2018","journal-title":"Immunobiology"},{"key":"10.1016\/j.intimp.2021.108463_b0160","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3389\/fimmu.2014.00491","article-title":"Macrophage cytokines: involvement in immunity and infectious diseases","volume":"5","author":"Arango Duque","year":"2014","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.108463_b0165","first-page":"13","article-title":"Tumor necrosis factor alpha (TNF-alpha) activates Jak1\/Stat3-Stat5B signaling through TNFR-1 in human B cells","volume":"13","author":"Miscia","year":"2002","journal-title":"Cell Growth Differ."},{"issue":"12","key":"10.1016\/j.intimp.2021.108463_b0170","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1002\/art.37691","article-title":"Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors","volume":"64","author":"Yarilina","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.intimp.2021.108463_b0175","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.4049\/jimmunol.160.8.4082","article-title":"Disparate roles for TNF-alpha and Fas ligand in concanavalin A-induced hepatitis","volume":"160","author":"Ksontini","year":"1998","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2021.108463_b0180","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/icb.2011.59","article-title":"Critical role of interleukin-17\/interleukin-17 receptor axis in mediating Con A-induced hepatitis","volume":"90","author":"Yan","year":"2012","journal-title":"Immunol. Cell Biol."},{"issue":"1","key":"10.1016\/j.intimp.2021.108463_b0185","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif","year":"2017","journal-title":"Cell Commun. Signal"},{"issue":"6","key":"10.1016\/j.intimp.2021.108463_b0190","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1053\/j.gastro.2009.08.004","article-title":"Myeloid STAT3 inhibits T cell-mediated hepatitis by regulating T helper 1 cytokine and interleukin-17 production","volume":"137","author":"Lafdil","year":"2009","journal-title":"Gastroenterology"},{"issue":"19","key":"10.1016\/j.intimp.2021.108463_b0195","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1016\/j.yexcr.2012.08.003","article-title":"Concanavalin-A triggers inflammatory response through JAK\/STAT3 signalling and modulates MT1-MMP regulation of COX-2 in mesenchymal stromal cells","volume":"318","author":"Akla","year":"2012","journal-title":"Exp. Cell Res."},{"issue":"2","key":"10.1016\/j.intimp.2021.108463_b0200","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.imlet.2009.01.005","article-title":"Tr1 regulatory T cells induced by ConA pretreatment prevent mice from ConA-induced hepatitis","volume":"122","author":"Ye","year":"2009","journal-title":"Immunol. Lett."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2021.108463_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2012.07.002","article-title":"The evolving story of macrophages in acute liver failure","volume":"147","author":"Yang","year":"2012","journal-title":"Immunol. Lett."},{"issue":"23","key":"10.1016\/j.intimp.2021.108463_b0210","doi-asserted-by":"crossref","first-page":"16513","DOI":"10.1074\/jbc.274.23.16513","article-title":"Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action","volume":"274","author":"Riley","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2021.108463_b0215","doi-asserted-by":"crossref","first-page":"G535","DOI":"10.1152\/ajpgi.00385.2006","article-title":"Characterization of the human intestinal CD98 promoter and its regulation by interferon-gamma","volume":"292","author":"Yan","year":"2007","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"2","key":"10.1016\/j.intimp.2021.108463_b0220","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.dld.2016.11.008","article-title":"CD98 siRNA-loaded nanoparticles decrease hepatic steatosis in mice","volume":"49","author":"Canup","year":"2017","journal-title":"Dig. Liver Dis."},{"issue":"6","key":"10.1016\/j.intimp.2021.108463_b0225","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0168-8278(96)80301-1","article-title":"A novel mechanism of murine hepatocyte death inducible by concanavalin A","volume":"25","author":"Leist","year":"1996","journal-title":"J. Hepatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921010997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921010997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:36:54Z","timestamp":1761586614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921010997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":45,"alternative-id":["S1567576921010997"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108463","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108463"}}